Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Vectura Group Plc (VEC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10105)・商品コード:DATA904C10105
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:71
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on a wide range of proprietary lung delivery technologies, including device and formulation capabilities. Vectura has a varied portfolio of drugs in clinical development, comprising several novel and generic programs that are partnered with several global biotechnology and pharmaceutical companies. Vectura is headquartered in Chippenham, Wiltshire, the UK.

Vectura Group Plc (VEC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vectura Group Plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 13
Partnerships 14
Ablynx Exercises Option for Licensing Agreement with Vectura 14
Vectura Enters into Agreement with Dynavax Technologies 15
Vectura Enters into Development and License Agreement with Janssen Biotech 16
Activaero Enters Into Research Agreement With Stanford University 17
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 18
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 19
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 20
Activaero Enters Into Co-Development Agreement With TransMIT 21
Tianjin KingYork Forms Joint Venture With Innovata For Asthma And COPD Drugs 22
Merger 23
SkyePharma Merges with Vectura 23
Licensing Agreements 25
Vectura Group Enters into Licensing Agreement with Pulmatrix 25
Sandoz Enters into Licensing Agreement with Vectura 26
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 27
Skyepharma Enters into Licensing Agreement with Lucideon 28
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 29
SkyePharma Enters into Option Agreement with Mundipharma 30
Vectura Enters into Licensing Agreement with US-Based Pharma Company for VR506 31
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 32
Equity Offering 33
SkyePharma Completes Private Placement Of Shares For US$187 Million 33
SkyePharma Completes Rights Offering Of Shares 34
Vectura Group Completes Private Placement Of Shares For US$46 Million 35
Ventaleon Spin Out from Activaero 36
Acquisition 37
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 37
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 38
Vectura Group Plc – Key Competitors 40
Vectura Group Plc – Key Employees 41
Vectura Group Plc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Sep 11, 2018: Vectura Group: Interim Results 43
Mar 21, 2018: Vectura Group: 2017 Preliminary Results 52
Mar 21, 2018: Vectura Group: 2017 Preliminary Results – Performance in-line with expectations, with strong in-market growth from key inhaled products 53
Sep 06, 2017: Vectura Group: 2017 Interim Results 55
Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 57
Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 59
Corporate Communications 60
Oct 22, 2018: Vectura group has announced the board change 60
Jul 16, 2018: Vectura Appoints Paul Fry as Chief Financial Officer and Executive Director 61
Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 62
Apr 20, 2018: Vectura Announces Senior Management Change 63
Apr 20, 2018: Vectura Group: Directorate Change – Chief Financial Officer 64
Mar 06, 2017: Vectura Group: Board Change 65
Clinical Trials 66
May 22, 2017: Positive outcomes of the Phase I clinical study on VR942 presented at the American Thoracic Society 113th annual conference 66
Jan 24, 2017: FDA approves IND to support Vectura’s wholly-owned programme VR647 in paediatric asthma 67
Other Significant Developments 68
Oct 24, 2017: Vectura Group: Ultibro Breezhaler continues to deliver strong underlying growth in Q3 68
Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products 69
Jan 11, 2017: Vectura Group: Pre-close update 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Vectura Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 13
Ablynx Exercises Option for Licensing Agreement with Vectura 14
Vectura Enters into Agreement with Dynavax Technologies 15
Vectura Enters into Development and License Agreement with Janssen Biotech 16
Activaero Enters Into Research Agreement With Stanford University 17
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 18
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 19
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 20
Activaero Enters Into Co-Development Agreement With TransMIT 21
Tianjin KingYork Forms Joint Venture With Innovata For Asthma And COPD Drugs 22
SkyePharma Merges with Vectura 23
Vectura Group Enters into Licensing Agreement with Pulmatrix 25
Sandoz Enters into Licensing Agreement with Vectura 26
Mundipharma Enters into Licensing Agreement with Vectura for VR2076 27
Skyepharma Enters into Licensing Agreement with Lucideon 28
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 29
SkyePharma Enters into Option Agreement with Mundipharma 30
Vectura Enters into Licensing Agreement with US-Based Pharma Company for VR506 31
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 32
SkyePharma Completes Private Placement Of Shares For US$187 Million 33
SkyePharma Completes Rights Offering Of Shares 34
Vectura Group Completes Private Placement Of Shares For US$46 Million 35
Ventaleon Spin Out from Activaero 36
GlaxoSmithKline May Acquire Vectura for USD1.62 Billion 37
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 38
Vectura Group Plc, Key Competitors 40
Vectura Group Plc, Key Employees 41
Vectura Group Plc, Subsidiaries 42

List of Figures
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vectura Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vectura Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10105)販売に関する免責事項を必ずご確認ください。
★調査レポート[Vectura Group Plc (VEC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆